Axiom Mission 4 will be Peggy Whitson’s second commercial human spaceflight mission with Axiom Space. Photo courtesy of Axiom

NASA veteran Peggy Whitson, a former student and professor at Houston’s Rice University, will command the global crew heading to the International Space Station aboard a private mission directed by Houston-based Axiom Space.

Whitson and her three fellow crew members arrived in Houston on August 6 to train with Axiom Space, NASA, and SpaceX for Axiom Mission 4. The mission is tentatively scheduled for October 2024.

The three astronauts joining Whitson will be:

  • Shubhanshu Shukla, the mission pilot, representing the Indian Space Research Organization
  • Sławosz Uznański, a mission specialist representing the European Space Agency and Poland
  • Tibor Kapu of Hungary, a mission specialist

Axiom Mission 4 will be Whitson’s second commercial human spaceflight mission with Axiom.

“With a culturally diverse crew, we are not only advancing scientific knowledge but also fostering international collaboration. Our previous missions set the stage,” Whitson says in a news release.

Axiom Mission 1 was the first private mission to the space station, Axiom Mission 2 launched the first Saudi woman into space, and

Axiom Mission 3 featured the first Turkish astronaut and first European Space Agency astronaut to fly on a commercial space mission.

With Axiom Mission 4, “we ascend even higher, bringing even more nations to low-Earth orbit and expanding humanity’s reach among the stars,” says Whitton.

From 1981 to 1985, Whitson conducted graduate work in biochemistry at Rice, where she earned a doctoral degree. She was a predoctoral and postdoctoral fellow.

Whitson’s vast experience includes:

  • Adjunct professor in biochemistry and genetics at the University of Texas Medical Branch in Galveston
  • Adjunct assistant professor in biochemistry and genetics at Rice
  • Research biochemist at NASA’s Johnson Space Center
  • Deputy division chief of medical sciences at Johnson Space Center.
  • Chief of station operations at NASA’s Astronaut Office
  • Chief of NASA’s Astronaut Corps
  • Crew member of three NASA space missions

Whitton and the three other astronauts still must gain approval for the Axiom mission from the five organizations that oversee the space station: NASA, the European Space Agency, Roscosmos (the Russian space agency), the Japan Aerospace Exploration Agency, and the Canadian Space Agency.

Axiom 4 “represents Axiom Space’s continued efforts to build opportunity for countries to research, innovate, test, and engage with people around the world while in low-Earth orbit,” says Michael Suffredini, CEO of Axiom Space. “This mission broadens horizons for nations with ambitious goals of advancing scientific, technological, and economic pursuits.”

This mission will emphasize scientific research, tech demonstrations, and space commercialization.

From Florida, the Axiom 4 crew will go to the International Space Station aboard a Falcon 9 rocket and Dragon spacecraft, both made by SpaceX. The crew is expected to spend up to 14 days at the space station.

Axiom Space has announced plans for its third commercial space launch and revealed details of its high-tech spacesuit. Photo courtesy of NASA

Houston space tech company secures third NASA mission, reveals new spacesuits

ready for liftoff

A Houston-based space tech company has revealed details on two of its commercial partnerships with NASA.

NASA and Axiom Space have again signed a mission order for a private astronaut mission to the International Space Station. The mission will commence sometime in November or on and will be from the agency’s NASA’s Kennedy Space Center in Florida. Axiom Mission 3 is the third mission of its kind and, according to a statement from NASA, is expected to be a 14-day trip.

The ISS's Multilateral Crew Operations Panel will approve four proposed crew members and two back up crew submitted by Axiom for the Ax-3 mission. The crew will be expected to train for their flight with NASA, international partners, and SpaceX beginning this spring, according to NASA.

“Axiom Space’s selection to lead the next private astronaut mission to the International Space Station enables us to continue expanding access to nations, academia, commercial entities, and emerging industries to research, test, and demonstrate new technologies in microgravity,” says Michael Suffredini, CEO and president of Axiom Space, in the release. “As NASA’s focus shifts back to the Moon and on to Mars, we are committed to transforming low-Earth orbit into a global space marketplace, where access to space moves beyond the partners of the space station to nations, institutions and individuals with new ideas fueling a thriving human economy beyond Earth.”

Axiom's historic first commercial launch was in spring of 2022, and Ax-2, which will launch the first Saudi astronauts to visit the ISS, is expected to launch this spring. In addition to these two missions, Axiom has been tasked by NASA to develop spacesuits and space station technology.

After several months of working on the suits, Axiom has revealed the details of the technology that will be worn by NASA astronauts returning to the moon on the Artemis III mission that's scheduled to land near the lunar south pole in 2025.

The newly revealed spacesuit will be worn by the first woman and first person of color to visit the moon. Photo courtesy of Axiom Space

“We’re carrying on NASA’s legacy by designing an advanced spacesuit that will allow astronauts to operate safely and effectively on the Moon,” says Suffredini in a statement from the company. “Axiom Space’s Artemis III spacesuit will be ready to meet the complex challenges of the lunar south pole and help grow our understanding of the Moon in order to enable a long-term presence there.”

Called the Axiom Extravehicular Mobility Unit, or AxEMU, the prototype was revealed at Space Center Houston’s Moon 2 Mars Festival today, March 15. According to Axiom, a full fleet of training spacesuits will be delivered to NASA by late this summer.

At the same time as the Ax-3 mission announcement, NASA also announced that it has selected Firefly Aerospace of Cedar Park, Texas, to carry multiple payloads to the far side of the Moon. According to NASA, the commercial lander will deliver two agency payloads, as well as communication and data relay satellite for lunar orbit, which is an European Space Agency collaboration with NASA.

The contract — awarded for around $112 million — is targeted to launch in 2026 through NASA’s Commercial Lunar Payload Services, or CLPS, initiative, and part of the agency’s Artemis program. It's the second award to Firefly under the CLPS initiative.

“The diversity of currently available commercial orbital human spaceflight opportunities is truly astounding. NASA’s commercial crew flights to the space station for our government astronauts paved the way for fully private missions to space like Inspiration4 and Polaris as well as private astronaut missions to the orbiting laboratory like the one we are announcing today,” says Phil McAlister, director of commercial space at NASA Headquarters in Washington, in the release. “We are starting to see the incorporation of space into our economic sphere, and it is going to revolutionize the way people see, use, and experience space.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.